Drug intelligence / Profile preview

gemcitabine + nedaplatin + BAI

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Bronchial Arterial Infusion

Overview

A combination chemotherapy regimen consisting of gemcitabine, nedaplatin, and bronchial arterial infusion (BAI) delivery method. Gemcitabine is a nucleoside metabolic inhibitor that works by replacing building blocks of nucleic acids during DNA elongation, arresting tumor growth and promoting apoptosis of malignant cells. Nedaplatin is a platinum derivative similar to cisplatin but with potentially reduced toxicity. The combination is administered via bronchial arterial infusion, a technique that delivers chemotherapy directly to the tumor site through the bronchial artery.

Targets

DNA

Beyond the preview

Go deeper on gemcitabine + nedaplatin + BAI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + nedaplatin + BAI.

Explore the full profile